Daklinza 60mg 28 Tablets

Description

DAKLINZA is a hepatitis C virus (HCV) NS5A inhibitor indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1 or 3 infection.

How to use:

• • 60 mg taken orally once daily with or without food in combination with sofosbuvir with or without ribavirin.

• • Recommended treatment duration: 12 weeks.

Caution & Warnings:

• • Risk of Hepatitis B Virus Reactivation

• • Bradycardia When Coadministered with Sofosbuvir and Amiodarone

Side Effects:

• • Headache, anemia, fatigue, and nausea

Ingredients:

• Daclatasvir 60Mg.